dc.contributor.author | Pettitt, SJ | |
dc.contributor.author | Lord, CJ | |
dc.date.accessioned | 2018-02-14T14:22:37Z | |
dc.date.issued | 2018-01-01 | |
dc.identifier | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000437006700002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9 | |
dc.identifier.citation | EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (2), pp. 83 - 94 (12) | |
dc.identifier.issn | 2380-8993 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1076 | |
dc.identifier.doi | 10.1080/23808993.2018.1438187 | |
dc.format.extent | 83 - 94 (12) | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | TAYLOR & FRANCIS LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Pharmacology & Pharmacy | |
dc.subject | Breast cancer | |
dc.subject | PARP inhibitors | |
dc.subject | BRCA1 | |
dc.subject | BRCA2 | |
dc.subject | treatment | |
dc.subject | synthetic lethality | |
dc.subject | CELL-FREE DNA | |
dc.subject | BRCA2 REVERSION MUTATIONS | |
dc.subject | SENSITIVE OVARIAN-CANCER | |
dc.subject | POLY(ADP-RIBOSE) POLYMERASE | |
dc.subject | HOMOLOGOUS RECOMBINATION | |
dc.subject | MAINTENANCE THERAPY | |
dc.subject | DOUBLE-BLIND | |
dc.subject | PHASE-II | |
dc.subject | SECONDARY MUTATIONS | |
dc.subject | REPAIR DEFECTS | |
dc.title | PARP inhibitors and breast cancer: highlights and hang-ups | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-02-02 | |
rioxxterms.versionofrecord | 10.1080/23808993.2018.1438187 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-01-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT | |
pubs.issue | 2 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Gene Function | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gene Function | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Gene Function | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gene Function | |
pubs.publication-status | Published | |
pubs.volume | 3 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Gene Function | |
dc.contributor.icrauthor | Pettitt, Stephen | |
dc.contributor.icrauthor | Lord, Christopher | |